Premaitha Health (NIPT) has updated investors attending its AGM that it believes its lead product “remains on target to be the first regulated CE marked ‘in vitro’ diagnostic product in the rapidly growing market for non-invasive prenatal screening”.
This is with development and launch preparations on schedule, with the test having performed well in verification studies and the company having received positive feedback on its quality systems and regulatory strategy. It is noted that “recruitment of commercialisation and technical support teams is ongoing” and that the company has presented the test at a number of conferences – with positive private and public body interest in the product from the UK, Europe, Asia and Australasia.
on ShareProphets | Comments